Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Erratum

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(2):669-670. Published online February 27, 2025

DOI: https://doi.org/10.3350/cmh.2024.0333e
Corrects: Clin Mol Hepatol 2024;30(4):807

View: 1015 Download: 46

Correspondence

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(2):e155-e157. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0723

View: 1163 Download: 46

Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2025;31(2):e149-e151. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0944

View: 928 Download: 19

Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Woo Hyun Paik, Do Hyun Park

Clin Mol Hepatol. 2025;31(2):e158-e160. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0989

View: 910 Download: 38

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(2):e163-e165. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.1057

View: 856 Download: 37

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(2):e169-e172. Published online December 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.1138

View: 847 Download: 26

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 1018 Download: 31

Correspondence to editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Yang Liu, Fan Peng, Siyuan Wang, Jinliang Xing

Clin Mol Hepatol. 2025;31(2):e166-e168. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1185

View: 805 Download: 31 Web of Science: 1 Crossref: 1

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 1107 Download: 23

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e210-e211. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1175

View: 1097 Download: 25

Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(2):e173-e175. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0001

View: 856 Download: 30 Web of Science: 1 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Hyuk Soo Eun

Clin Mol Hepatol. 2025;31(2):e215-e217. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0035

View: 841 Download: 22

Correspondence

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0079

View: 749 Download: 37 Web of Science: 1 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 770 Download: 27

Correspondence

Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):e197-e199. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2025.0085

View: 780 Download: 31

TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Anja Tiede, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(2):e176-e179. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0135

View: 797 Download: 20 Crossref: 1

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e212-e214. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0100

View: 655 Download: 21

GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e189-e191. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0120

View: 752 Download: 30 Crossref: 1

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e161-e162. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0121

View: 711 Download: 29

Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e180-e182. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0125

View: 760 Download: 24

Reply to Correspondence

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0128

View: 1015 Download: 30

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Georg Semmler, Lorenz Balcar, Mattias Mandorfer

Clin Mol Hepatol. 2025;31(2):e224-e225. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0149

View: 739 Download: 36

Correspondence

The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0152

View: 760 Download: 15 Crossref: 1

Correspondence to editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):e206-e207. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0164

View: 725 Download: 24

Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”

Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0166

View: 976 Download: 31

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 601 Download: 19 Web of Science: 1 Crossref: 1

Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”

Haolong Li, Song Liu, Xu Wang, Li Wang, Tengda Xu, Yongzhe Li

Clin Mol Hepatol. 2025;31(2):e194-e196. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0181

View: 768 Download: 32

Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”

Rong-Qi Sun, Shao-Lai Zhou

Clin Mol Hepatol. 2025;31(2):e192-e193. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0183

View: 696 Download: 22

Reply to Correspondence

Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):e228-e231. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0195

View: 810 Download: 25

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):e232-e233. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0203

View: 572 Download: 22

Viewed By 11519	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7233	MAFLD: How is it different from NAFLD?
Viewed By 5521	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5171	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4591	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 349	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 328	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 219	MAFLD: How is it different from NAFLD?
Cited By 113	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Others